1US Food and Drug Administration.Guidance for Industry:Uncomplicated and Complicated Skin and Skin Structure Infections-Developing Antimicrobial Drug for Treatment[J/OL].http://www.fda.gov,1998-07 -01.
2US Food and Drug Administration.Guidance for Industry:Developing Antimicrobial Drugs-general Considerations for Clinical Trials[J/OL].http://www.fda.gov,1998 -07 -05.
3US Food and Drug Administration.Guidance for Industry:Evaluating Clinical Studies of Antimicrobials in The Division of Anti-Infective of Drug Products[J/OL].http://www.fda.gov,1997-02-07.
5PELLANDA C, OTTIKER E, STRUB C, et al. Topical bioavailability of triamcinolone acetonide: effect of dose and application frequency [J]. Arch Dermatol Res, 2006, 298 (5):221-230.
6HERKENNE C, NAIK A, KALIA Y N, et al. Dermatopharmacokinetic prediction of topical drug bioavailability in vivo [J]. J Invest Dermatol, 2007, 127 (4):887-894.
7WIEDERSBERG S, LEOPOLD C S, GUY R H. Dermatopharmacokinetics of betamethasone 17-valerate: Influence of formulation viscosity and skin surface cleaning procedure [J]. Eur J Pharm Biopharm, 2009,71 (2):362-366.
8CHAURASIA C S, MULLER M, BASHAW E D, et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives[J]. Pharm Res, 2007, 24(5): 1014-1025.
9BENFELDT E, HANSEN S H, VOLUND A, et al. Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method[J]. J Invest Dermatol, 2007, 127 (1): 170-178.
10MATHY F X, LOMBRY C, VERBEECK R K, et al. Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat[J]. J Pharm Sci, 2005, 94 (1):144-152.
